Dan Wang, Zong-Hao Wang, Chun-Bao Wang, Zhi-Chun Wu
{"title":"The Diagnostic Performance of <sup>68</sup>Ga-PSMA-11 PET/MRI for the Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-analysis.","authors":"Dan Wang, Zong-Hao Wang, Chun-Bao Wang, Zhi-Chun Wu","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Our meta-analysis aimed to evaluate the diagnostic performance of <sup>68</sup>Ga-PSMA-11 PET/MRI for biochemical recurrence of prostate cancer.</p><p><strong>Methods: </strong>We systematically and comprehensively searched all available studies until May 2023 in the PubMed and Embase databases. Studies evaluating <sup>68</sup>Ga-PSMA-11 PET/MRI in men with prostate cancer biochemical recurrence were included. We appraised the quality of studies using a tailored Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. For each meta-analysis, we used the DerSimonian and Laird method. We first transformed proportions with the Freeman-Tukey double arcsine transformation, and then confidence intervals were calculated using the Jackson method. Meta-regression and sensitivity analysis were conducted to explore heterogeneity sources. Furthermore, we conducted subgroup analysis according to the PSA levels.</p><p><strong>Results: </strong>Overall, 13 studies with 738 patients were included in the analysis. The pooled overall detection rates of <sup>68</sup>Ga-PSMA-11 PET/MRI in detecting recurrent PCa after definitive treatment were 74% (95% CI, 68%-79%). For patients with PSA under 0.5 ng/mL, the detection rate was 55 %. The detection rates were 79 %, 76 % and 87 % for the subgroup PSA levels of 0.5-0.99, 1.0-1.99 and over 2.0 ng/mL.</p><p><strong>Conclusion: </strong><sup>68</sup>Ga-PSMA-11 PET/MRI has a good detection rate for biochemical recurrence of prostate cancer. However, large sample, multi-center studies are still needed to verify and expand on our conclusion.</p>","PeriodicalId":49173,"journal":{"name":"Iranian Journal of Public Health","volume":"53 6","pages":"1224-1235"},"PeriodicalIF":1.3000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11488562/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Public Health","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Our meta-analysis aimed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET/MRI for biochemical recurrence of prostate cancer.
Methods: We systematically and comprehensively searched all available studies until May 2023 in the PubMed and Embase databases. Studies evaluating 68Ga-PSMA-11 PET/MRI in men with prostate cancer biochemical recurrence were included. We appraised the quality of studies using a tailored Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. For each meta-analysis, we used the DerSimonian and Laird method. We first transformed proportions with the Freeman-Tukey double arcsine transformation, and then confidence intervals were calculated using the Jackson method. Meta-regression and sensitivity analysis were conducted to explore heterogeneity sources. Furthermore, we conducted subgroup analysis according to the PSA levels.
Results: Overall, 13 studies with 738 patients were included in the analysis. The pooled overall detection rates of 68Ga-PSMA-11 PET/MRI in detecting recurrent PCa after definitive treatment were 74% (95% CI, 68%-79%). For patients with PSA under 0.5 ng/mL, the detection rate was 55 %. The detection rates were 79 %, 76 % and 87 % for the subgroup PSA levels of 0.5-0.99, 1.0-1.99 and over 2.0 ng/mL.
Conclusion: 68Ga-PSMA-11 PET/MRI has a good detection rate for biochemical recurrence of prostate cancer. However, large sample, multi-center studies are still needed to verify and expand on our conclusion.
期刊介绍：
Iranian Journal of Public Health has been continuously published since 1971, as the only Journal in all health domains, with wide distribution (including WHO in Geneva and Cairo) in two languages (English and Persian). From 2001 issue, the Journal is published only in English language. During the last 41 years more than 2000 scientific research papers, results of health activities, surveys and services, have been published in this Journal. To meet the increasing demand of respected researchers, as of January 2012, the Journal is published monthly. I wish this will assist to promote the level of global knowledge. The main topics that the Journal would welcome are: Bioethics, Disaster and Health, Entomology, Epidemiology, Health and Environment, Health Economics, Health Services, Immunology, Medical Genetics, Mental Health, Microbiology, Nutrition and Food Safety, Occupational Health, Oral Health. We would be very delighted to receive your Original papers, Review Articles, Short communications, Case reports and Scientific Letters to the Editor on the above mentioned research areas.
分享
京公网安备 11010802042870号
京ICP备2023020795号-1
求助内容：
应助结果提醒方式：
扫码关注我们
